Navigation Links
Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
Date:5/13/2009

FARMINGDALE, N.Y., May 13 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced their attendance at the 22nd Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS), which was held in Dallas, TX, April 26-29, 2009, and is widely regarded as the premier educational wound care-focused program in the United States. Also, the SAWC/WHS symposium is the official meeting of the Association for the Advancement of Wound Care (AAWC), a pre-eminent multi-disciplinary organization for wound care. Misonix exhibited and demonstrated its SonicOne(R) Ultrasonic Wound Cleansing and Debridement System to many of the approximately 2,300 clinicians in attendance.

As part of the therapeutic educational program, Oscar Alvarez, Ph.D., FAPWCA, Director of the Center for Curative and Palliative Wound Care at Calvary Hospital, Bronx, NY, and an Associate Professor of Medicine at New York Medical College, presented data on the use of the SonicOne for wound debridement compared to standard "sharps" debridement. Dr. Alvarez's data, for more than 75 patients, with about half of the patients receiving SonicOne treatment and the other half receiving "sharps" treatment, demonstrated statistically significant reductions in the time to healing and the number of debridement procedures when SonicOne was selected as the method of choice.

From humble beginnings in 1988, when a small group of nurses and physicians interested in this emerging discipline created a mission and vision to provide an interdisciplinary forum on wound care, the SAWC/WHS has grown, becoming the largest annual gathering of wound care clinicians in the United States. The SAWC/WHS partnership reflects the need for clinicians to better understand the research and science behind wound management in pursuit of optimal patient outcomes.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Misonix is pleased to demonstrate its commitment to the large and rapidly growing wound care market by supporting important educational programs like SAWC/WHS and ASWC," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "The wound care product platform, we believe, can make an important contribution to improving patient outcomes and we are gratified when data is presented by clinical experts that support our investment in wound care Research and Development."

About Misonix:

Misonix, Inc. (NASDAQ: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces Participation in Annual Diabetic Foot Global Conference
2. Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009
3. Misonix Announces New HIFU Distribution Agreement For Portugal
4. Misonix Announces New HIFU Distribution Agreement for Romania and Bulgaria
5. Misonix Announces New Distribution Agreement for Portugal
6. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
7. Misonix Announces New Distribution Agreement for Belgium and Luxembourg
8. Misonix Announces New Sales Agency Agreement for Eastern Europe
9. Misonix Announces New Distribution Agreement for Israel
10. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
11. Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients ... With this in mind, SIGVARIS has created a new line of anti-embolism stockings ... rest and provide the benefits of graduated compression when transitioning from recovery to ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael ... headquartered in Hamilton County, is embarking on a charity drive with the aim ... new homes for orphaned or neglected senior dogs in the Cincinnati region, and ...
(Date:12/8/2016)... ... 08, 2016 , ... The Compretta Insurance Agency, a family owned insurance and ... the Hancock County area, is announcing the launch of a charity effort aimed at ... County Food Pantry has worked for more than 30 years to meet the food ...
(Date:12/7/2016)... ... December 07, 2016 , ... Students attending Envision’s ... unique opportunity to get hands-on experience in an emergency medical simulation, When Care ... to gain invaluable, real-life medical skills that are critical success in a future ...
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is a simple, ... and tightening the skin of the face to create more youthful features. While ... very little downtime, Silhouette Instalift is a novel, minimally invasive facial procedure that ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... with cutting edge next-generation sequencing and bioinformatics expertise; AITbiotech Pte ... the Genome Institute of Singapore (GIS) ... joint venture between Novogene and AITbiotech – will establish a ... Singapore .   The new centre will ...
(Date:12/8/2016)... -- Eli Lilly and Company (NYSE: LLY ... a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, ... a biomarker of cell proliferation, after two weeks of ... during the official press program at the 2016 San ... or in combination with the non-steroidal aromatase-inhibitor anastrozole, in ...
(Date:12/7/2016)... Dec. 7, 2016 KEY FINDINGS ... benefits such as reducing loss of blood during ... cardiac arrests, rapid recovery after surgeries, and decreasing ... be segmented into convective warming system, surface warming ... turn reduce the stay at hospitals thus, lowering ...
Breaking Medicine Technology: